Verona Pharma plc Verona Pharma Plc : Miscellaneous
September 19 2017 - 7:47AM
UK Regulatory
TIDMVRP
Issue of Shares
September 19, 2017, London - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA)
("Verona Pharma"), a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for respiratory
diseases, announces that it will issue 133,333 new ordinary shares in
the capital of the Company (the "New Shares") following an exercise of
share options by N+1 Singer Capital Markets Limited. Application has
been made to the London Stock Exchange for the New Shares to be admitted
to trading on AIM, with dealings expected to commence on 22 September
2017 ("Admission").
Following Admission, the Company will have a total of 105,017,401
Ordinary Shares in issue each carrying one voting right. The Company
does not hold any Ordinary Shares in Treasury. This figure of
105,017,401 Ordinary Shares may be used by shareholders as the
denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest
in, the share capital of the Company under the FCA's Disclosure and
Transparency Rules.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapeutics for the treatment
of respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a
bronchodilator and an anti-inflammatory agent in a single compound. In
clinical trials, treatment with RPL554 has been observed to result in
statistically significant improvements in lung function as compared to
placebo and has shown clinically meaningful and statistically
significant improvements in lung function when added to two commonly
used bronchodilators as compared to either bronchodilator administered
as a single agent. Verona Pharma is developing RPL554 for the treatment
of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and
potentially asthma.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker) SNELVeronaPharma@stifel.com
Stewart Wallace / Jonathan Senior / Ben Maddison
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
September 19, 2017 07:46 ET (11:46 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024